Harbour Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Harbour Investments’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229	Hold	55	–	–	﹤0.01%	4526
2026 Q1	$193	Buy	+55	New	+$176	﹤0.01%	4441
2025 Q2	–	Sell	-100	Closed	-$333	–	3666
2025 Q1	$333	Hold	100	–	–	﹤0.01%	3382
2024 Q4	$740	Hold	100	–	–	﹤0.01%	3227
2024 Q3	$939	Hold	100	–	–	﹤0.01%	3104
2024 Q2	$802	Hold	100	–	–	﹤0.01%	3027
2024 Q1	$1.48K	Buy	+100	New	+$1.16K	﹤0.01%	2850
2021 Q4	–	Sell	-502	Closed	-$12K	–	3154
2021 Q3	$12K	Hold	502	–	–	﹤0.01%	2569
2021 Q2	$13K	Buy	502 +2	+0.4%	+$52	﹤0.01%	2585
2021 Q1	$16K	Buy	+500	New	+$20.7K	﹤0.01%	2330

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Harbour Investments's IOVA Position: Q2 2026 in Review

Harbour Investments held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 55 shares worth $229. The position accounts for ﹤0.01% of the portfolio, ranked #4526.

Harbour Investments first reported a position in IOVA in Q1 2021 and has held it in 10 quarters since. The position peaked at $16K in Q1 2021. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Harbour Investments held 55 shares of Iovance Biotherapeutics worth $229 as of Q2 2026.
Harbour Investments left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4526 holding.
Harbour Investments first reported a position in Iovance Biotherapeutics in Q1 2021 and has held it in 10 quarters since.
Harbour Investments's Iovance Biotherapeutics position peaked at $16K in Q1 2021.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.